AB-FUBINACA is a novel synthetic cannabinoid compound. Members of this group produce cannabis-like effects when administered.
AB-FUBINACA was originally developed by Pfizer in 2009 as an analgesic medication, but was not pursued for human use.
Subsequently in 2012, it was discovered as an ingredient in synthetic cannabis blends in Japan along with a related compound AB-PINACA which had not previously been reported.
Cannabinoids are commonly smoked or vaporized to achieve a quick onset of effects and rapid offset. AB-FUBINACA is orally active when dissolved in a lipid, which can increase the duration significantly.
Like other cannabinoids, it is insoluble in water but dissolves in ethanol and lipids.
AB-FUBINACA, or N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide, is a synthetic indazole cannabinoid drug as it contains a substituted indazole core.
A 4-substituted fluorophenyl group is bound to this indazole core through a methyl group at R1 of the indazole. This indazole is substituted at R3 with a carboxamide group.
The terminal amine of this carboxamide is bonded to a substituted propyl chain with an aminocarbonyl group at R1 and a methyl group at R2.
Although this substance has not been formally studied, from analysis of the structure, it is presumed that this product has a similar binding profile to that of other cannabinoids and matches many of the in vivo properties of Δ9-THC.
AB-FUBINACA exhibits its range of effects via full agonism of both the CB1 and CB2 cannabinoid receptors, with some selectivity for CB2. However, the role of these interactions and how they result in the cannabinoid high experience continues to remain elusive
Sedation – Generally, the effects on the user’s energy levels are primarily sedating. This encourages one to relax, and (at higher doses) fall asleep.
This can be suppressed by simply forcing oneself to engage in physical activities.
Spontaneous physical sensations .
The “body high” of AB-FUBINACA may be described as a warm, soft, pleasurable, all-encompassing tingling sensation that spreads over the body after initial ingestion.
It maintains a consistent presence that quickly rises with the onset and hits its limit once the peak has been reached before immediately dissipating.
At high doses, this can become uncomfortably intense.
Motor control loss –
This substance causes a partial to moderate suppression of motor control which intensifies proportional to dose but rarely results in a complete inability to walk and perform basic movements.
Appetite enhancement – As with many other cannabinoids,.
AB-FUBINACA causes an increase in appetite, known colloquially as “the munchies” in popular American and United Kingdom culture. Clinical studies and survey data have found that cannabis increases food enjoyment and interest in food.
This is thought to be due to the way in which endocannabinoids in the hypothalamus activate cannabinoid receptors that are responsible for maintaining food intake.
Changes in felt gravity AB-FUBINACA can cause vertigo with which the environment appears to be spinning or oscillating.
At moderate doses, it can spontaneously induce the sensation of falling, which can be overwhelming and uncomfortable.
Perception of bodily heaviness or Perception of bodily lightness